Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — H1 2021 Earnings Presentation
21 slides from Lytix Biopharma ASA's earnings presentation, Aug 27, 2021
Slide 1: Second Quarter and First Half of 2021 Results
SECOND QUARTER AND FIRST HALF OF 2021 RESULTS 27 August 2021
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Lytix Biopharma's presenters
Lytix Biopharma’s presenters Øystein Rekdal - CEO and co-founder • Dr. Rekdal is an international authority on oncolytic molecules with his post-doctoral research forming the basis of Lytix Biopharma’s oncolytic molecule discovery platform • Has held a series of increasingly senior roles with Lytix,
Slide 4: The lead cancer asset
THE LEADCANCER ASSET AN ONGOING THE MISSING PROBLEM REVOLUTION LINK First Asset entering Phase II is Cancer the second development Even though immune Lytix’s molecules leading cause of death checkpoint inhibitors represent a missing link globally and responsible have recently in current cancer for a
Slide 5: An introduction to Lytix Biopharma
An introduction to Lytix Biopharma ▪ Clinical stage immuno-oncology biotech company with an opened Phase II trial of the lead candidate LTX-315 in the US, targeting several cancer indications ▪ Next generation drug candidate LTX-401, developed for treatment of deep-seated tumors, will be ready for a
Slide 6: Highlights of second quarter and first half of 2021
Highlights of second quarter and first half of 2021 Phase I data published in Clinical Cancer Research: LTX-315 generates immune responses in the majority of the treated patients with significant reduction of distant non-treated tumors in 30% of the patients Creating Clinical Phase II study with LTX
Slide 7: A unique oncolytic molecule platform generating therapeutic assets
A unique oncolytic molecule platform that already has generated several exciting therapeutic assets
Slide 8: ATLAS IT-05 opened in H1-21: US Phase II study with LTX-315
ATLAS IT-05 opened in H1-21: Building clinical evidence through launching our US clinical Phase II study with LTX-315 combined with pembrolizumab Study opened in July at MD Anderson in Texas. Ongoing recruitment process. Aim of the study: ‒ Document LTX-315`s ability to enhance number of cancer pati
Slide 9: The checkpoint inhibitor market is expected to grow, yet they fail most patients
The checkpoint inhibitor market is expected to reach USD 55 bn by 2025, yet they fail to adress most cancer patients A majority of patients don’t respond to checkpoint inhibitors Tumor characteristics reduce checkpoint inhibitor effectiveness Checkpoint inhibitor monotherapy failure rate Responders
Slide 10: Oncolytic molecules can boost checkpoint inhibitor efficacy
Our solution: Oncolytic molecules can boost checkpoint inhibitor efficacy significantly by tackling heterogeneity and creating “hot” tumors Adapted from Zhou, Cell Death & Disease 2016. Zhou, Oncotarget 2015. Forveille, Cell Cycle 2015. Eike, Oncotarget, 2015. Camilio, OncoImmunology 2014, Camilio,
Slide 11: Early signs of significant synergies with LTX-315 followed by checkpoint inhibitors
Early signs of significant synergies with LTX-315 followed by checkpoint inhibitor therapy July May September Extensive metastasis Started LTX-315 injections Progression with new lesions and 2009 started on pembrolizumab Chemotherapy until October 2012 2010 2011 2013 2014 2014 74 year old male Compl
Slide 12: Early clinical data in late stage triple negative breast cancer
Early clinical data for in hard-to-treat late stage triple negative breast cancer is encouraging Clinical benefit observed in Early Clinical Data Phase I/II 38% of patients despite dose LTX-315 + pembrolizumab (Keytruda®) in triple negative breat cancer variations The tumor objective response rate (
Slide 13: LTX-315 + Pembrolizumab effects not obtained with Pembrolizumab alone
LTX-315 + Pembrolizumab display effects not obtained with Pembrolizumab alone in hard-to-treat triple negative breast cancer LTX-315 + pembrolizumab works better than pembrolizumab alone in TNBC patients with liver metastases Source: Keynote 086 Pembrolizumab SA study in PD1+ TNBC (170 patients)
Slide 14: Phase II study with LTX-315 at Herlev hospital fully recruited
Phase II study with LTX-315 at Herlev hospital in Denmark fully recruited ATLAS-IT-04: ‒ A small proof of principle study ‒ Recruitment completed (n=6) Sarcoma ‒ Current therapy is often ineffective for patients with recurrent or metastatic disease ‒ Often Cold tumors (low number of T cells) Adoptiv
Slide 15: Second generation LTX-401 for deep seated tumors
Second generation LTX-401 offers a unique way to treat deep seated tumors such as liver cancer Commentary LTX-401 is engineered for the purpose of reaching deep into the body So that our technology can help patients with LTX-401 is a small oncolytic hepatocellular carcinoma, metastatic colorectal ca
Slide 16: Board of directors strengthened with industry and capital markets experts
Board of directors strengthened with industry and capital markets experts Gert W. Munthe, chair Brynjar Forbergskog • Founder and Managing Partner of Herkules Capital - a • CFO (1989-2005) and CEO (2005-19) of Torghatten, leading Nordic private equity player which grew from being a small locally bas
Slide 17: Technology validated by commercial partnerships and academic collaborations
Lytix’s technology has been extensively validated by ongoing commercial partnerships and top-tier academic collaborations A partnership in skin cancer Partnerships in T cell therapy US-based biotech focused on the development and Iovance is a US-based late-stage biotech developing novel cancer comme
Slide 18: Financial review of Q2 and first half of 2021
Financial review of Q2 and first half of 2021 Unaudited Unaudited Unaudited Unaudited 3 months 3 months 6 months 6 months 12 months ended ended ended ended ended (in NOK thousands) Notes 30.06.2021 30.06.2020 30.06.2021 30.06.2020 2020 Total operating income 1,640 1,111 23,201 1,245 6,678 Total oper
Slide 19: Private placement and listing
Private placement and listing: Significant interest from new investors and commitment from existing owners Oversubscribed private placement of NOK 225m attracted strong support and interest from Norwegian and international investors Use of proceeds to initiate and complete a Phase II trial of LTX-31
Slide 20: Highlights of second quarter and first half of 2021
Highlights of second quarter and first half of 2021 Creating Achieving Securing Partnering with Products of Financial Excellent Innovators Value Milestones Capabilities
Slide 21: Q&A
Q&A IR enquiries: gjest.breistein@lytixbiopharma.com